Verrica doses first U.S. patient in COVE-3 trial for common warts

June 22, 2026 8:05 AM

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the first U.S. patient has been dosed in COVE-3, the second pivotal clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found